Follicular lymphoma transformation to dual translocated Burkitt-like lymphoma: improved disease control associated with radiation therapy

  • Stacey M. Parker
  • Horatiu Olteanu
  • Peter VanTuinen
  • Colleen A. Lawton
  • Christopher J. Schultz
  • Kathleen K. Christians
  • Timothy S. Fenske
Case Report

Abstract

Dual translocated (or “dual hit”) lymphomas are highly aggressive B cell neoplasms associated with an extremely poor prognosis. The optimal treatment for these lymphomas remains undefined. We present two cases of follicular lymphoma with transformation to Burkitt-like lymphoma. In both cases dual translocations involving both the bcl-2 and c-myc loci were present. Each patient underwent intensive induction immunochemotherapy followed by autologous stem cell transplantation and radiation therapy. The first patient received post-transplant mediastinal radiation and developed recurrence in multiple areas outside of the radiation field. The second patient received total body irradiation as part of the conditioning regimen, and is without recurrence 18 months after transplant, and 24 months after diagnosis of the dual translocated lymphoma. We review dual translocation B cell lymphoma in the setting of transformation from follicular lymphoma, and suggest a potential role for total body irradiation in the management of this highly aggressive non-Hodgkin lymphoma.

Keywords

Burkitt-like lymphoma Dual translocated lymphoma Double-hit lymphoma Autologous hematopoietic stem cell transplantation Transformed lymphoma Radiation therapy 

References

  1. 1.
    Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996;14:925–34.PubMedGoogle Scholar
  2. 2.
    Thomas DA, Faderl S, O’Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006;106:1569–80.CrossRefPubMedGoogle Scholar
  3. 3.
    Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin’s lymphoma. J Clin Oncol. 1995;13:588–95.PubMedGoogle Scholar
  4. 4.
    Zelenetz AD, Hamlin P, Kewalramani T, Yahalom J, Nimer S, Moskowitz CH. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin’s lymphoma. Ann Oncol. 2003;14(Suppl 1):i5–10.CrossRefPubMedGoogle Scholar
  5. 5.
    Thompson JA, Fisher RI, Leblanc M, et al. Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438). Blood. 2008;111:4048–54.CrossRefPubMedGoogle Scholar
  6. 6.
    Blum KA, Lozanski G, Byrd JC. Adult Burkitt leukemia and lymphoma. Blood. 2004;104:3009–20.CrossRefPubMedGoogle Scholar
  7. 7.
    Nakamura N, Nakamine H, Tamaru J, et al. The distinction between Burkitt lymphoma and diffuse large B-Cell lymphoma with c-myc rearrangement. Mod Pathol. 2002;15:771–6.CrossRefPubMedGoogle Scholar
  8. 8.
    McClure RF, Remstein ED, Macon WR, et al. Adult B-cell lymphomas with Burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior. Am J Surg Pathol. 2005;29:1652–60.CrossRefPubMedGoogle Scholar
  9. 9.
    Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer (IARC); 2008.Google Scholar
  10. 10.
    Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med. 2006;354:2431–42.CrossRefPubMedGoogle Scholar
  11. 11.
    Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354:2419–30.CrossRefPubMedGoogle Scholar
  12. 12.
    Al-Tourah AJ, Gill KK, Chhanabhai M, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26:5165–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Kanungo A, Medeiros LJ, Abruzzo LV, Lin P. Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis. Mod Pathol. 2006;19:25–33.CrossRefPubMedGoogle Scholar
  14. 14.
    Le Gouill S, Talmant P, Touzeau C, et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica. 2007;92:1335–42.CrossRefPubMedGoogle Scholar
  15. 15.
    Macpherson N, Lesack D, Klasa R, et al. Small noncleaved, non-Burkitt’s (Burkitt-Like) lymphoma: cytogenetics predict outcome and reflect clinical presentation. J Clin Oncol. 1999;17:1558–67.PubMedGoogle Scholar
  16. 16.
    Niitsu N, Okamoto M, Miura I, Hirano M. Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia. 2009.Google Scholar
  17. 17.
    Voorhees PM, Carder KA, Smith SV, Ayscue LH, Rao KW, Dunphy CH. Follicular lymphoma with a Burkitt translocation–predictor of an aggressive clinical course: a case report and review of the literature. Arch Pathol Lab Med. 2004;128:210–3.PubMedGoogle Scholar
  18. 18.
    Hecht JL, Aster JC. Molecular biology of Burkitt’s lymphoma. J Clin Oncol. 2000;18:3707–21.PubMedGoogle Scholar
  19. 19.
    Tomita N, Tokunaka M, Nakamura N, et al. Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations. Haematologica. 2009;94:935–43.CrossRefPubMedGoogle Scholar
  20. 20.
    Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood. 2009;114:2273–9.Google Scholar
  21. 21.
    Sweetenham JW. Highly aggressive lymphoma in adults. Hematol Oncol Clin N Am. 2008;22:965–78.CrossRefGoogle Scholar
  22. 22.
    Rizzieri DA, Johnson JL, Niedzwiecki D, et al. Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma. Cancer. 2004;100:1438–48.CrossRefPubMedGoogle Scholar
  23. 23.
    Network NCC. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin’s lymphomas V.1.2009; (2009).Google Scholar
  24. 24.
    Heerema NA, Raimondi SC, Anderson JR, et al. Specific extra chromosomes occur in a modal number dependent pattern in pediatric acute lymphoblastic leukemia. Genes Chromosom Cancer. 2007;46:684–93.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2009

Authors and Affiliations

  • Stacey M. Parker
    • 1
  • Horatiu Olteanu
    • 2
  • Peter VanTuinen
    • 2
  • Colleen A. Lawton
    • 3
  • Christopher J. Schultz
    • 3
  • Kathleen K. Christians
    • 4
  • Timothy S. Fenske
    • 5
  1. 1.Department of Internal MedicineThe Medical College of WisconsinMilwaukeeUSA
  2. 2.Department of PathologyThe Medical College of WisconsinMilwaukeeUSA
  3. 3.Department of Radiation OncologyThe Medical College of WisconsinMilwaukeeUSA
  4. 4.Department of SurgeryThe Medical College of WisconsinMilwaukeeUSA
  5. 5.Division of Neoplastic Diseases and Related DisordersMedical College of WisconsinMilwaukeeUSA

Personalised recommendations